logo
Dr Elisabeth Whipp, innovative oncologist who spoke out on television against ‘postcode prescribing'

Dr Elisabeth Whipp, innovative oncologist who spoke out on television against ‘postcode prescribing'

Yahoo2 days ago

Dr Elisabeth Whipp, who has died aged 77, was a leading oncologist who was suspended from Bristol Royal Infirmary in 2002 for carrying out an unapproved form of radiotherapy treatment; she was later cleared of wrongdoing, amid suggestions that her real transgression had been to make public criticisms of the vagaries of NHS funding.
She made headlines in 1997 when she spoke out in an edition of Channel 4's Dispatches against the increasing prevalence of 'postcode prescribing'. She had been treating two breast cancer patients with the drug Taxol; one was from Taunton, and her treatment was funded by the Somerset Health Authority, but the second woman, from Bristol, had to negotiate an overdraft to raise £10,000 to pay for the drugs herself.
'There is always embarrassment about patients having to buy a drug,' Liz Whipp complained. 'After many years in the NHS I'm not used to bargaining with money.' In response, the Avon Health Authority argued that the money was more urgently needed for breast-care nurses.
Liz Whipp was back in the news in early 2003 when it emerged that she had been suspended some weeks earlier amid questions over the experimental radiotherapy she had been prescribing.
Previously, the location of tumour beds had been difficult to pinpoint and radiation had to be directed over the whole breast, with care taken to keep the dose low enough to minimise the risk of damaging the heart. Liz Whipp's innovation had been to use newly developed MRI scanners to locate the tumour beds more precisely and then target higher doses of radiation at a smaller area.
Some of her colleagues considered that she was underestimating the risks that these higher doses posed, and Bristol Royal Infirmary took the decision to investigate her for carrying out treatment that had not been authorised by the National Institute for Health and Care Excellence (Nice). 'If we allow unfettered clinical freedom to take place we will end up with situations where patients will receive treatments which are not in accordance with Nice guidance,' a hospital spokesman insisted.
Liz Whipp suggested in later life, however, that certain male colleagues had not approved of her breaking the omerta around NHS funding and had been waiting for an opportunity to take her down a peg. She was suspected of having broken rules by encouraging patients to complain to their MPs about NHS restrictions on the availability of drugs such as Herceptin.
The suspension of Liz Whipp became a cause célèbre, with the shadow health secretary Liam Fox arguing that she was the victim of an NHS culture that victimised whistleblowers: 'I can't see any case to say this doctor acted in an unprofessional way. In fact, it seems to have been quite the opposite and she has acted in the interest of her patients. Dr Whipp has been suspended for what we regard as totally spurious reasons.'
Her former patients queued up to praise her. One 77-year-old man told the press: 'She is an extremely compassionate woman and very sympathetic. She was the best doctor I could have had and I think that she saved my life.'
Liz Whipp – who pointed out that, of 542 patients given the experimental treatment, only two had seen their cancer return – claimed that she had in fact always followed Nice guidelines. Nevertheless she was suspended for nearly two years while the United Bristol Healthcare NHS Trust investigated her.
She was completely exonerated, but although she returned to work she was deeply pained by the experience and grieved by the thought that many patients had died unnecessarily while her treatment programme was on hold.
The daughter of Brian Whipp, an academic, Elisabeth Clare Whipp was born on September 9 1947. She read medicine at Lady Margaret Hall, Oxford, and worked at the London Hospital and the Royal Free Hospital before moving to Bristol in the early 1980s.
As a long-serving radiotherapy consultant at the Royal Infirmary's Haematology and Oncology Centre, Liz Whipp gained a reputation for speaking her mind. In 1983 she made waves by criticising Prince Charles for visiting the Bristol Cancer Help Centre, a charity that was advocating the rejection of orthodox medicine in favour of alternative treatments: 'I do feel strongly about the Prince of Wales making a Royal tour of something that's full of bogus notions.'
She became renowned for her innovative thinking, which was not confined to the development of radiotherapy. Convinced that the mental welfare of patients played a large role in their recovery, she appointed a clinical psychologist, Dr James Brennan, to work with her at Bristol; this was the first full-time clinical psychology post in cancer services in the NHS.
Experience taught her that when it came to coping with cancer, 'single women… do better, because they tend to have women friends, whereas a lot of married women have husbands they can't talk to about health.'
Described by one friend as 'a statuesque woman, combining a pre-Raphaelite beauty with the charisma of a Valkyrie', Liz Whipp was a keen painter and a fine pianist and singer: on one occasion she found herself in a musical duel with Germaine Greer, competing to see who could give the better rendering of the Queen of the Night's aria from The Magic Flute. She had recently finished the first draft of a gleefully horrific thriller, utilising her medical background to devise a series of especially gruesome murders.
She created a beautiful garden at her home in Clifton, finding room in a relatively small space for a pool of koi carp, a stream, quiet pathways, a grotto and a bamboo grove. Her wide circle of friends was treated to extravagant garden parties complete with fireworks.
On one occasion a neighbour disgruntled by the noise spitefully padlocked the gates at the end of her drive to inconvenience the guests – a futile gesture, as no guest at one of Liz Whipp's parties left until they absolutely had to.
Elisabeth Whipp, born September 9 1947, died April 26 2025
Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

NHS Confederation and Beamtree launch data analytics platform for NHS trusts
NHS Confederation and Beamtree launch data analytics platform for NHS trusts

Yahoo

time4 hours ago

  • Yahoo

NHS Confederation and Beamtree launch data analytics platform for NHS trusts

The UK's National Health Service (NHS) Confederation has partnered with health technology company Beamtree to introduce The Evolve Collaborative, which aims to enhance the use of operational data at NHS trusts in England. The initiative is focused on offering acute care services, enhancing patient outcomes and increasing efficiency. It combines Beamtree's analytics platform with the NHS Confederation's expertise in convening and improvement, with the aim to benchmark performance, understand variations and apply data-driven enhancements to processes. NHS Confederation chief executive Matthew Taylor said: 'The Evolve Collaborative seeks to empower clinicians, boards and operations leaders with the data they need. 'The collaborative will be a driven by our members and will encourage them to be curious about who else is doing things differently, and to ask 'why'. 'By combining predictive analytics with peer learning, we're giving NHS leaders the tools and support they need to drive real, measurable improvement." The Evolve Collaborative's analytics platform uses AI and machine learning to predict future trends. This will allow NHS trusts to identify challenges and assess the potential impact of different interventions. The platform is supported by tailored dashboards and tools designed for various roles within the NHS. A key component of the partnership is the formation of peer-to-peer learning communities, which are facilitated by experts in improvement. These aim to provide a secure environment for members to exchange best practices and jointly develop solutions to common challenges. Evolve Collaborative membership is currently available to NHS Trusts and Foundation Trusts providing acute services in England. Beamtree chief executive Marek Stepniak said: 'Our experience with Health Roundtable in Australia and New Zealand has delivered measurable improvements in healthcare delivery. 'These insights have already helped providers on the other side of the world achieve tangible outcomes and we look forward to bringing this proven model of learning and collaboration to the UK." "NHS Confederation and Beamtree launch data analytics platform for NHS trusts" was originally created and published by Hospital Management, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

The NHS truths the Left don't want you to hear
The NHS truths the Left don't want you to hear

Yahoo

time5 hours ago

  • Yahoo

The NHS truths the Left don't want you to hear

Until very recently, Health Secretary Wes Streeting tried to market himself as a radical health reformer, who is not afraid to poke sacred cows. While his reform-minded rhetoric always remained at a highly-abstract and general level, Streeting deserved some credit for it, because he did not have to do this. He had the courage to say things which he knew would rub some people up the wrong way, not least the Corbynite wing of his own party. Sadly, that brief period of NHS candour is now officially over. Streeting, the self-styled reformer, is no more. He and his colleagues have fully retreated into their comfort zone. During the recent local election campaign, Labour distributed a leaflet that showed a mock medical bill, and a doctor holding up a credit card reader. The message was clear: vote for us, because this is what the other lot want to do to you. On Twitter/X, Labour are now frequently posting dire warnings about the alleged evils of insurance-based healthcare systems. This is exactly that old-school NHS cultism which Streeting used to disavow until five minutes ago. It may work for him. The NHS may be falling apart, but the cult around is still going strong. In the eyes of its keenest defenders, the NHS can do no wrong. They have quietly dropped the old cliché about the NHS being 'the envy of the word', and replaced it with a slightly more subtle version, which goes something like this: Once upon a time, the NHS used to be the best healthcare system in the world. But then, from 2010 on, it was systematically defunded. It was deliberately run into the ground, so that it can be privatised more easily. A privatised system would mean luxury healthcare for the rich, and Wild West medicine for the poor. None of these claims are true. Let's have a look at each of them in turn. The NHS was never the best healthcare system in the world. The idea that it ever was can be traced back to a ranking compiled by the Commonwealth Fund, an American healthcare think tank, which relies on a very unusual methodology, in which medical outcomes only account for a fifth of the total score. This matters, because on medical outcomes, the NHS has always been one of the worst-performing healthcare systems in the developed world – as even the Commonwealth Fund study shows. There is no turning point after which the NHS's performance suddenly deteriorated. It was just never good in the first place. At the end of the 2010s, age-adjusted real NHS spending per capita was only marginally higher than it had been in the beginning of the decade. Put differently, the NHS budget only just about kept pace with population growth, population ageing, and inflation. This clearly constituted a slowdown in spending increases compared to the previous decade. But it does not constitute a 'defunding'. In any case: that period of relative spending restraint is already over again. The NHS budget was given a massive boost during the pandemic, which has only been partially reversed. Public healthcare spending in the UK stands at just under 9% of GDP: one of the highest levels in the world. Conspiracy theories about secret plans to privatise the NHS have been around for decades. I wrote a report on this three years ago, for which I went through the news archives, and I found warnings about the NHS's imminent demise from every year since 1980. But somehow, it never happens. The NHS remains an unusually state-centred system. Most healthcare systems, including tax-funded ones, use a mix of public, private for-profit and private non-profit providers. There are no plans – secret or otherwise – to privatise the NHS. More's the pity. Because there is nothing wrong with private healthcare systems. There are good examples of private, insurance-based healthcare systems, most notably in the Netherlands and Switzerland, which are nothing like the dreaded system of the US. These systems cover everybody: poor people are exempt from health insurance premiums and co-payments. Under these systems, rich and poor alike get faster access to medical treatment, and better medical outcomes, than they would on the NHS. The only thing these people don't get is a naff feel-good mythology around their health systems. Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.

MRI-Led Surveillance Stratifies Prostate Cancer Risk
MRI-Led Surveillance Stratifies Prostate Cancer Risk

Medscape

time6 hours ago

  • Medscape

MRI-Led Surveillance Stratifies Prostate Cancer Risk

In a cohort study of patients with prostate cancer, MRI-led risk-adapted active surveillance demonstrated effectiveness in risk stratification. The approach showed that MRI visibility and the presence of secondary Gleason pattern 4 at baseline were associated with higher rates of progression and treatment initiation. METHODOLOGY: Researchers analysed 1150 patients who started active surveillance between February 2000 and July 2023, including those with a Gleason score (GS) ≤ 3 + 4, prostate-specific antigen (PSA) < 20 ng/mL, and at least two MRI scans. Participants underwent PSA testing three to four times in the first year, followed by biannual testing; MRI was performed at baseline and 12 months, with an additional MRI scan performed at 24 months for those with MRI-visible lesions at baseline. Patients were stratified into four groups on the basis of baseline risk factors, including GS (3 + 3 vs 3 + 4) and MRI visibility ("non-visible disease" vs "visible disease"). The primary outcome was event-free survival, with an event defined as the detection of GS ≥ 4 + 3 or the initiation of any prostate cancer treatment. The median follow-up duration was 64 months per person overall and 72 months for 732 patients without an event. At baseline, 64% of patients had GS 3 + 3 and 36% had GS 3 + 4; 49% of those with GS 3 + 4 had MRI-visible disease. TAKEAWAY: Event-free survival rates varied significantly on the basis of the risk group, with 5-year rates of 91% for non-visible GS 3 + 3, 71% for MRI-visible GS 3 + 3, 71% for non-visible GS 3 + 4, and 44% for MRI-visible GS 3 + 4 disease. Among 487 patients who underwent follow-up biopsies, histological upgrade to GS ≥ 4 + 3 occurred in 67 patients; non-visible GS 3 + 3 cases had 5- and 10-year rates of 1.2% and 6.1%, respectively, for histological progression to GS ≥ 4 + 3, while the rates were 17% and 43% for those with MRI-visible GS 3 + 4 disease at baseline, respectively. Progression to nodal or bone metastases was observed in 10 patients, occurring only in those who had declined recommended follow-up MRI and/or biopsies. The 10-year rate of commencing treatment was 28% for those with non-visible GS 3 + 3 disease vs 85% for those with MRI-visible GS 3 + 4 disease and 46% for those with non-visible GS 3 + 4 disease vs 54% for those with MRI-visible GS 3 + 3 disease. IN PRACTICE: "Results from our cohort suggest that AS [active surveillance] patients can be monitored safely with MRI, and the decision to biopsy was based on MRI findings and PSA changes. Prospective, multicentre, clinical trials are required and currently being designed to further evaluate this approach," the authors wrote. SOURCE: This study was led by Cameron Englman, Division of Surgery & Interventional Science, University College London, London, England. It was published online on May 27, 2025, in European Urology . LIMITATIONS: Compared with time-based biopsy protocols, the MRI-led risk-adapted approach may underestimate histological progression. Additionally, as a cohort study without a strict protocol, practice evolved alongside contemporary pathology and radiology standards, with MRI quality, reporting standards, and the definition of radiological progression varying over time, particularly improving after the adoption of the PRECISE recommendations in 2016. DISCLOSURES: This study did not receive any specific funding. Several authors reported receiving consulting fees and grants and having other ties with various sources.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store